Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle

Withdrawn before enrolling · Not applicable

Conditions studied: Pancreatic Cancer, Lymphadenopathy, Cholangiocarcinoma

In brief

The primary objective of this proposed prospective randomized, multi-center study is to evaluate the capability of the new 22G SharkCore™ needle to obtain tissue specimens and to compare its performance against the standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle in the evaluation of solid mass lesions in the pancreas and gastrointestinal tract. The secondary objective is to determine the ability of the 22G SharkCore™ needle system to yield histologic tissue.

Key facts

Study ID

NCT02872831

Run by

Thomas Jefferson University

People needed

0

Starts

2016-07-01

Expected to finish

2017-11-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Eligible patients will include anyone >18 years old that presents to the participating clinical institutions and requires an endosonographic evaluation for the presence of a solid-appearing mass lesion amenable to EUS access, and no contraindication to FNA as determined by standard clinical care

You may not qualify if…

• Refusal to participate in the study
• Solid-appearing mass lesion that in not amenable to EUS guided needle access for tissue acquisition
• Patients with incomplete medical records
• Pregnant patients
• Prisoners
• INR > 1.5
• Platelets < 50,000

Where it is running

• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.